biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Aug 04, 2015 12:50pm

96 Views

Post# 23987349

RE:RE:Whatever happened to the Sandhoff LSD study?

Sir Holler,

Thanks for the clip from the MD&A. Perhaps they put the Sandhoff study on the back burner once the Scarpa study got rolling. From the September 2014 news release on the Sandhoff study, it sure sounded like they were ready to treat the mice then next month instead of putting their fusion proteins into the freezer and not using precious knockout mice that they were so excited to have generated.

BDAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload